Clinical trials: Placebo Response
Asthma
Effect of Inhaled TD-8236 on Allergen-induced Asthmatic Response
This will be a randomized, double-blind, placebo-controlled study. The study will use a three-period, six-sequence, complete-block, cross-over study design to characterize two doses of inhaled TD-8236 compared to placebo in…
- Trial name
- NCT04150341
- Testing
- TD-8236
- Where
- 2 sites in United Kingdom
- Volunteers
- 24 people
- Sponsor
- Theravance Biopharma
Rheumatoid Arthritis
Dose-Escalating Study of BG9924 in Combination With Methotrexate in Active Rheumatoid Arthritis
This Phase 2a study is designed to evaluate the safety and tolerability of multiple subcutaneous (SC) doses of BG9924, administered in a cohort dose-escalation fashion, in patients with active rheumatoid arthritis (RA) who have…
- Trial name
- NCT00292422
- Testing
- BG9924
- Where
- 10 sites in United States, Poland
- Volunteers
- 50 people
- Sponsor
- Biogen
Chronic Non-specific Low Back Pain
Dose-Response Characterization of VER-01 in the Treatment of Patients With Chronic Non-specific Low Back Pain
Dose-response characterization of VER-01 in patients with chronic non-specific low back pain (CLBP) for whom drug treatment is indicated and previous optimized treatments with non-opioid analgesics have not led to sufficient pain…
- Trial name
- RESPONSE (NCT06475001)
- Testing
- VER-01
- Where
- United Kingdom
- Volunteers
- 652 people
- Sponsor
- Vertanical GmbH
Depressive Disorder, Major
A Home-based Study Using Mobile Technology to Test Whether BI 1358894 is Effective in People With Depression
This is a home-based study in adults with depression. People who have been diagnosed with Major Depressive Disorder can participate in the study.
- Trial name
- NCT04423757
- Testing
- BI 1358894
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Boehringer Ingelheim
Trigeminal Neuralgia
An Efficacy and Safety Study of Basimglurant (NOE-101) in Patients With Trigeminal Neuralgia.
Trigeminal neuralgia (TN), also called "tic douloureux", is the most common form of craniofacial neuropathic pain and is considered the cause of one of the most painful afflictions known in medical practice.
- Trial name
- NCT05217628
- Testing
- Basimglurant
- Where
- 34 sites in United States, Denmark and 6 more
- Volunteers
- 166 people
- Sponsor
- Noema Pharma AG
Major Depressive Disorder (MDD), Major Depressive Disorder With Psychotic Features
Study of Lurasidone as Adjunctive Treatment in Patients With Major Depressive Disorder With Inadequate Response to Antidepressant Monotherapy
This Phase 3, multicenter, randomized, double-blind, placebo-controlled clinical trial is designed to evaluate the efficacy and safety of lurasidone as adjunctive therapy in adult patients with major depressive disorder (MDD) who…
- Trial name
- NCT07781293
- Testing
- Lurasidone, Background Antidepressant Therapy
- Volunteers
- 364 people
- Sponsor
- Bukwang Pharmaceutical
Tuberculosis
Safety and Immune Responses After Vaccination With Two Investigational RNA-based Vaccines Against Tuberculosis in BCG Vaccinated Volunteers
This is a two-part randomized, placebo-controlled, observer-blind, safety and dose-finding Phase Ib/IIa study. This study will evaluate up to four dose levels of the BNT164 investigational vaccines (BNT164a1 and BNT164b1) to…
- Trial name
- NCT05547464
- Testing
- BNT164a1, BNT164b1
- Where
- 8 sites in Mozambique, South Africa
- Volunteers
- 497 people, healthy volunteers welcome
- Sponsor
- BioNTech SE
Breast Adenocarcinoma, Stage II Breast Cancer AJCC v6 and v7
TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and Surgery
This phase II trial studies how well TPIV100 and sargramostim work in treating patients with HER2 positive, stage II-III breast cancer that has residual disease after chemotherapy prior to surgery.
- Conditions
- Breast Adenocarcinoma, Stage II Breast Cancer AJCC v6 and v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7
- Trial name
- NCT04197687
- Testing
- Multi-epitope HER2 Peptide Vaccine TPIV100, Pertuzumab, Sargramostim
- Where
- 30 sites in United States
- Volunteers
- 480 people
- Sponsor
- Academic and Community Cancer Research United
HIV Infections
Safety of and Immune Response to an Adenoviral HIV-1 Vaccine in Healthy Adults
Successful control of the HIV epidemic will require a safe and effective vaccine to be developed. A successful vaccine will need to stimulate a widespread immune response.
- Trial name
- NCT00618605
- Testing
- Ad26.ENVA.01 HIV-1 vaccine
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
SARS-CoV-2 Infection, COVID-19
A Study Looking at the Effectiveness, Immune Response, and Safety of a COVID-19 Vaccine in Adults in the United Kingdom
This is a study to evaluate the efficacy, immune response, and safety of a coronavirus disease 2019 (COVID-19) vaccine called SARS-CoV-2 rS with Matrix-M1 adjuvant in adults aged 18-84 years in the United Kingdom.
- Trial name
- NCT04583995
- Testing
- SARS-CoV-2 rS/Matrix M1-Adjuvant, Licensed seasonal influenza vaccine
- Where
- 33 sites in United Kingdom
- Volunteers
- 15,185 people, healthy volunteers welcome
- Sponsor
- Novavax
Postoperative Pain
An International Trial to Evaluate the Efficacy and Safety of SABER®-Bupivacaine for Postoperative Pain Control in Patients Undergoing Hysterectomy
The objective is to identify the optimal dose of SABER-Bupivacaine for postoperative pain control in patients undergoing hysterectomy on the basis of pharmacokinetics, efficacy and safety evaluations.
- Trial name
- NCT00993226
- Testing
- SABER-Bupivacaine Treatment 1a, Bupivacaine HCl Treatment 1c, SABER-Bupivacaine Treatment 2a
- Where
- 14 sites in France, Germany and 4 more
- Volunteers
- 115 people
- Sponsor
- Durect
Juvenile Idiopathic Arthritis
A Study of Tocilizumab in Patients With Active Polyarticular Juvenile Idiopathic Arthritis
This 3-part study evaluated the efficacy and safety of tocilizumab in patients with active polyarticular-course juvenile idiopathic arthritis who have an inadequate response to, or were intolerant of methotrexate.
- Trial name
- NCT00988221
- Testing
- Tocilizumab
- Where
- 69 sites in United States, Argentina and 13 more
- Volunteers
- 188 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
(C2013-0302) Safety and Efficacy of Escalating Doses of SAN-300 in Patients With Rheumatoid Arthritis
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Escalating Doses of SAN-300 in Patients with Active Rheumatoid Arthritis with Inadequate Response to Disease-Modifying Anti-rheumatic Drug(s).
- Trial name
- NCT02047604
- Testing
- SAN-300 0.5 mg/kg QW, SAN-300 1.0 mg/kg QW, SAN-300 2.0 mg/kg QOW
- Where
- 12 sites in United States
- Volunteers
- 41 people
- Sponsor
- Bausch Health Americas, Inc.
Rheumatoid Arthritis
A Study in Moderate to Severe Rheumatoid Arthritis
The purpose of this study is to determine whether baricitinib is superior to placebo in the treatment of participants with moderately to severely active Rheumatoid Arthritis (RA) who have had an inadequate response to…
- Trial name
- RA-BEAM (NCT01710358)
- Testing
- Adalimumab, Baricitinib, Methotrexate
- Where
- 213 sites in United States, Argentina and 26 more
- Volunteers
- 1,307 people
- Sponsor
- Eli Lilly and Company
Healthy
Effects of a Placebo Probiotic on Gut Health and General Well-being in Individuals With Mild Gastrointestinal Symptoms
The present study is aimed at exploring whether positive expectations of receiving a three-week treatment with a probiotic supplement (in fact a placebo) improve symptoms of gastrointestinal distress and promote physical and…
- Trial name
- PlaCIBO (NCT06720558)
- Testing
- Control-no treatment
- Where
- Italy
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Catholic University of the Sacred Heart
Open-Angle Glaucoma, Ocular Hypertension
Safety and Efficacy Study of DE-104 Ophthalmic Solution to Treat Open-angle Glaucoma or Ocular Hypertension
To investigate the dose-response relationship of DE-104 ophthalmic solution in lowering intraocular pressure (IOP) in subjects with Primary Open-Angle Glaucoma or Ocular Hypertension
- Trial name
- NCT00650338
- Testing
- DE-104 ophthalmic solution, low concentration, DE-104 ophthalmic solution, medium concentration, DE-104 ophthalmic solution, high concentration
- Where
- 14 sites in United States
- Volunteers
- 165 people
- Sponsor
- Santen Inc.
Bruxism
Botulinum Toxin-A for Bruxism Using Digital Occlusal Analysis
Bruxism is a repetitive jaw-muscle activity that may lead to tooth wear, muscle pain, headaches, and functional limitations. Current diagnostic approaches mainly rely on self-reported symptoms and clinical examination findings…
- Trial name
- NCT07640035
- Testing
- Botulinum Toxin-A injection
- Where
- Turkey (Türkiye)
- Volunteers
- 36 people
- Sponsor
- Bilecik Seyh Edebali Universitesi
Bacterial Vaginosis, Vulvovaginal Candidiasis
Efficacy, Safety, and Dose-response of a Live Biotherapeutic Product in Women With Acute Vaginal Infection
The purpose of this clinical trial is to investigate the clinical efficacy and safety of a Live Biotherapeutic Product (BGY-1601-VT) intended as a first line of treatment in cases of acute vaginal infection without upfront…
- Trial name
- ELINA (NCT06450990)
- Testing
- BGY-1601-VT
- Volunteers
- 165 people
- Sponsor
- NEXBIOME THERAPEUTICS
Biliary Atresia
Evaluation of Maralixibat in Biliary Atresia Response Post-Kasai
A study to evaluate the efficacy and safety of maralixibat in infants with Biliary Atresia (BA) after Hepatoportoenterostomy (HPE, also known as the Kasai procedure).
- Trial name
- EMBARK (NCT04524390)
- Testing
- Maralixibat
- Where
- 22 sites in United States, China and 6 more
- Volunteers
- 75 people
- Sponsor
- Mirum Pharmaceuticals, Inc.
Multicentric Castleman's Disease
A Study to Evaluate the Efficacy and Safety of CNTO328 Plus Best Supportive Care in Multicentric Castleman's Disease
The purpose of this study is to demonstrate that CNTO 328 when administered in combination with best supportive care (BSC) is superior to BSC in terms of durable tumor and symptomatic response (complete response or partial…
- Trial name
- NCT01024036
- Testing
- Siltuximab, Best Supportive Care (BSC)
- Where
- 56 sites in United States, Australia and 21 more
- Volunteers
- 79 people
- Sponsor
- Janssen Research & Development, LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.